• WHAT ARE IN-SILICO CLINICAL TRIALS?

    An In Silico Clinical Trial is the use of individualised computer simulation in the design, development and regulatory evaluation of a medicinal product, medical device, or medical intervention. Currently. Biomedical

    Read more »
  • Funding

    The project has received funding from the European Union’s Horizon 2020 research and innovation programme

    Read more »
  • InSilc Modules

    InSilc has developed a range of state-of-the-art modules to predict BVS performance

    Read more »
  • Who are we?

    The InSilc Consortium includes 12 partners from 8 different EU countries and one US partner.

    Read more »

Home

Check out the latest video from the InSilc project that describes the InSilc Platform and activities.

 

The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.

The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.

 

New-fig